Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3401 USD | -4.68% | +0.56% | -44.25% |
Mar. 21 | Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.27M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -14M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.25
x | P/E ratio 2025 * |
-0.52
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.15% |
1 day | -4.68% | ||
1 week | +0.56% | ||
Current month | -17.21% | ||
1 month | -18.09% | ||
3 months | -26.39% | ||
6 months | -47.88% | ||
Current year | -44.25% |
Managers | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CEO | Chief Executive Officer | 65 | 14-12-07 |
David Hale
FOU | Founder | 75 | 14-12-07 |
Kyri van Hoose
DFI | Director of Finance/CFO | - | 21-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 14-12-07 |
Gerry Proehl
CEO | Chief Executive Officer | 65 | 14-12-07 |
Wendell Wierenga
BRD | Director/Board Member | 76 | 16-09-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.3401 | -4.68% | 9,619 |
24-04-24 | 0.3568 | +5.03% | 18,879 |
24-04-23 | 0.3397 | -3.33% | 23,509 |
24-04-22 | 0.3514 | +9.44% | 37,777 |
24-04-19 | 0.3211 | -5.06% | 28,521 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.25% | 2.27M | |
-2.57% | 103B | |
+0.63% | 95.71B | |
+1.40% | 22.02B | |
-17.30% | 20.9B | |
-9.23% | 17.85B | |
-42.83% | 16.21B | |
-14.73% | 15.52B | |
+4.74% | 13.86B | |
+32.97% | 12.04B |
- Stock Market
- Equities
- DRMA Stock